Returns Breakdown
| Return on Investment | (663.52) | |
| Return on Assets | (1.5) | |
| Return on Equity | 0.4 | |
| Return Capital | 0.65 | |
| Return on Sales | (7.76) |
Are NORTHWEST (OTC:NWBO) institutional investors starting to hold back?
 | By Rifka Kats | Macroaxis Story |
NORTHWEST BIOTHERAPEUTICS PPandE Turnover is quite stable at the moment as compared to the past year. The company's current value of PPandE Turnover is estimated at 0.0161. Accounts Payable Turnover is expected to rise to 0.0217 this year, although the value of Net Income Per Employee will most likely fall to (6.2 M). The goal of this thesis is to forecast a future value of NORTHWEST BIOTHERAPEUTICS using technical analysis. What exactly are NORTHWEST BIOTHERAPEUTICS institutional investors should expect in September?
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Ellen Johnson
This firm has a beta of 0.7722. Let's try to break down what NORTHWEST's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NORTHWEST BIOTHERAPEUTICS will likely underperform. The beta indicator helps investors understand whether NORTHWEST BIOTHERAPEUTICS moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if NORTHWEST deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Northwest Biotherapeutics. Your research has to be compared to or analyzed against Northwest Biotherapeutics' peers to derive any actionable benefits. When done correctly, Northwest Biotherapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Northwest Biotherapeutics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Northwest Biotherapeutics. Regardless of method or technology, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Northwest Biotherapeutics
Watch out for price decline
Please consider monitoring Northwest Biotherapeutics on a daily basis if you are holding a position in it. Northwest Biotherapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other otcs. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Northwest Biotherapeutics stock to be traded above the $1 level to remain listed. If Northwest Biotherapeutics otc stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Northwest Biotherapeutics's Liquidity
Northwest Biotherapeutics financial leverage refers to using borrowed capital as a funding source to finance Northwest Biotherapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Northwest Biotherapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Northwest Biotherapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Northwest Biotherapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Northwest Biotherapeutics's total debt and its cash.
Breaking down Northwest Biotherapeutics Further
The latest price rise of NORTHWEST BIOTHERAPEUTICS INC may encourage institutional investors to take a closer look at the firm as it closed today at a share price of 0.33 on 1,469,634 in trading volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 30 days investing horizon is currently 7.49. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the NORTHWEST BIOTHERAPEUTICS partners.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Northwest Biotherapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.